Literature DB >> 20843172

New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.

Katrine R Schønnemann, Mette Yilmaz, Maria Andersen, Per Pfeiffer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20843172     DOI： 10.3109/0284186X.2010.509738

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  2 in total

1.  The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine.

Authors:  Seyyed-Hossein Yahyazadeh-Jabbari; Nasser Malekpour; Bahram Salmanian; Hossein Foodazi; Masoud Salehi; Farsad Noorizadeh
Journal:  Iran J Cancer Prev       Date:  2013

2.  Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Authors:  Yuan Tian; Qun Zhao; Yong Li; Liqiao Fan; Zhidong Zhang; Xuefeng Zhao; Bibo Tan; Dong Wang; Peigang Yang
Journal:  Gastroenterol Res Pract       Date:  2021-07-22       Impact factor: 2.260
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.